Small molecule · developed by Hutchmed
HMPL-295S1 is an orally administered agent given once daily in 28-day cycles in a clinical trial of patients with advanced malignant solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04908046 | Phase 1 | Advanced Malignant Solid Tumors | Completed | HCM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Malignant Solid Tumors
Updated Oct 18, 2026. Something wrong or missing? Report it on the HCM page.
See HCM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
HCM catalysts and pipeline →